which developed the drug before licensing it to Morphosys in 2010, will receive a $25 million milestone payment and a royalty on worldwide net sales. Before any rebates or discounts Monjuvi's ...
The drug accounts for $517.5 million of the milestone ... test plamotamab in combination with their CD19-targeted antibody Monjuvi (tafasitamab) – plus Bristol-Myers Squibb's Revlimid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback